/KRYS

KRYS Stock - Krystal Biotech, Inc.

Q: What is the analyst price target for KRYS?

Analyst price target information is not currently available for KRYS.

Q: What is KRYS's market cap?

Market capitalization information is not currently available for KRYS.

Healthcare|Biotechnology|NASDAQ

$291.93+7.28%

+$19.80 (+7.28%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-8.5%upside

Target: $267.12

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for KRYS

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.46

52W High$292.89

52W Low$122.80

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$290.51M	$50.70M	N/A	N/A	N/A
Gross Profit	$270.45M	$47.60M	N/A	N/A	$-1,851,000
Gross Margin	93.1%	93.9%	N/A	N/A	N/A
Operating Income	$65.69M	$-109,727,000	$-145,196,000	$-68,275,000	$-32,999,000
Net Income	$89.16M	$10.93M	$-139,975,000	$-69,570,000	$-32,167,000
Net Margin	30.7%	21.6%	N/A	N/A	N/A
EPS	$3.12	$0.40	$-5.49	$-3.13	$-1.71

Company Overview

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Visit Website

Earnings History & Surprises

KRYS

Beat Rate

56%

Last 18 quarters

Avg Surprise

+8.0%

EPS vs Estimate

Beats / Misses

10/7

1 met exactly

Latest EPS

$2.66

Q4 2025

EPS Surprise History

Q1 24

+178.9%

$0.30vs$-0.38

Q2 24

-80.0%

$0.03vs$0.15

Q3 24

+72.0%

$0.86vs$0.50

Q4 24

+1.1%

$0.91vs$0.90

Q1 25

+17.8%

$1.52vs$1.29

Q2 25

-13.0%

$1.20vs$1.38

Q3 25

+19.4%

$1.29vs$1.08

Q4 25

+137.5%

$2.66vs$1.12

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 4, 2026	—	—	—	—
Q1 2026	Feb 18, 2026	$1.62	—	—	—
Q4 2025	Nov 3, 2025	$1.12	$2.66	+137.5%	✓ BEAT
Q3 2025	Aug 4, 2025	$1.08	$1.29	+19.4%	✓ BEAT
Q2 2025	May 6, 2025	$1.38	$1.20	-13.0%	✗ MISS
Q1 2025	Feb 19, 2025	$1.29	$1.52	+17.8%	✓ BEAT
Q4 2024	Nov 4, 2024	$0.90	$0.91	+1.1%	✓ BEAT
Q3 2024	Aug 5, 2024	$0.50	$0.86	+72.0%	✓ BEAT
Q2 2024	May 6, 2024	$0.15	$0.03	-80.0%	✗ MISS
Q1 2024	Feb 26, 2024	$-0.38	$0.30	+178.9%	✓ BEAT
Q4 2023	Nov 6, 2023	$-1.10	$-0.67	+39.1%	✓ BEAT
Q3 2023	Aug 7, 2023	$-0.42	$-1.25	-197.6%	✗ MISS
Q2 2023	May 8, 2023	$-1.41	$-1.76	-24.8%	✗ MISS
Q1 2023	Feb 27, 2023	$-1.39	$-1.25	+10.1%	✓ BEAT
Q4 2022	Nov 7, 2022	$-1.23	$-1.17	+4.9%	✓ BEAT
Q3 2022	Aug 8, 2022	$-1.08	$-1.10	-1.9%	✗ MISS
Q2 2022	May 9, 2022	$-0.96	$-0.99	-3.1%	✗ MISS
Q1 2022	Feb 28, 2022	$-0.76	$-0.94	-23.7%	✗ MISS
Q4 2021	Nov 8, 2021	$-0.75	$-0.70	+6.7%	✓ BEAT
Q3 2021	Aug 9, 2021	$-0.74	$-0.74	0.0%	= MET

Frequently Asked Questions about KRYS

What is KRYS's current stock price?

Krystal Biotech, Inc. (KRYS) is currently trading at $291.93 per share. The stock has moved +7.28% today.

What is the analyst price target for KRYS?

The average analyst price target for KRYS is $267.00, based on 1 analyst.

What sector is Krystal Biotech, Inc. in?

Krystal Biotech, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is KRYS's market cap?

Krystal Biotech, Inc. has a market capitalization of $8.47 billion, making it a mid-cap company.

Does KRYS pay dividends?

No, Krystal Biotech, Inc. does not currently pay a dividend to shareholders.